InnoCare Pharma Limited (09969) reported that as of October 31, 2025, its authorized share capital remained at 25,000,000,000 ordinary shares with a total nominal value of USD50,000.

For shares listed on The Stock Exchange of Hong Kong Limited, the number of issued shares excluding treasury shares stood at 1,493,798,235 at month-end, reflecting a decrease of 800,000 shares from the preceding month. Treasury shares of this class increased by 800,000 to 2,486,000. The total number of issued shares, standing at 1,496,284,235, remained unchanged overall.

Regarding shares listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, the Company reported no movement, with 268,359,717 shares in issue. There were also no changes stemming from warrants, convertibles, or any other share option arrangements during October.

Separately, a share repurchase took place on October 10, 2025, at HKD14.71 per share, resulting in 800,000 shares being classified as treasury shares. The Company also noted that no new shares were issued pursuant to its 2023 RMB Share Incentive Scheme or its 2024 RMB Share Incentive Scheme within the reporting period. The existing incentive programs continue to allow for future allocations under their approved limits, but no additional issuances were made during October.